New CAR T cell therapy for B cell cancers
Official title: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
Funded at Luminary Therapeutics, INC. · NIH-10698759 · Data updated 2026-11-12
This study is testing a new treatment using special immune cells to help people with mantle cell lymphoma, aiming to make the therapy work better and last longer by using a unique approach to boost the immune response against the cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luminary Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $397,934 |
| NIH project number | 1R44CA278021-01A1 |
| Project ID | NIH-10698759 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma or other B cell malignancies who have not responded to existing therapies.
✕Less likely to help
Patients with non-B cell malignancies or those who have not been diagnosed with any form of cancer may not benefit from this research.
What this research studies
This research investigates a novel therapy using allogeneic CAR T cells that target B cell malignancies, specifically mantle cell lymphoma. The approach focuses on utilizing B cell activating factor (BAFF) to enhance the effectiveness of the treatment by improving T cell persistence and reducing the chances of cancer cells evading therapy. By leveraging a unique ligand-based CAR design in gamma delta T cells, the research aims to create a more durable and effective treatment option for patients. This innovative method seeks to overcome limitations of current therapies that primarily target pan B cell antigens.
Why it matters
Potential benefit: If successful, this research could provide a more effective and long-lasting treatment option for patients with B cell malignancies.
How similar studies have gone: While CAR T cell therapies have shown success in treating various cancers, this specific approach using BAFF and gamma delta T cells is novel and has not been widely tested.
Where this research is happening
-
Luminary Therapeutics, INC.
Minneapolis, United States Active
Researchers
- Principal investigator: Lewis, Andrew Kyle — Luminary Therapeutics, INC.
- Study coordinator: Lewis, Andrew Kyle
Related research
Other NIH-funded projects on the same topics.
-
Allogeneic BAFF-based CAR T Cells for B Cell Cancers
A new donor-derived CAR T cell therapy using BAFF ligands is being explored to treat B cell malignancies like mantle cell lymphoma, aiming for better persistence and easier access than current autologous treatments.
-
Off-the-shelf BAFF-targeting CAR T for B‑cell cancers
An off-the-shelf CAR T-cell therapy that uses the BAFF ligand to target B‑cell cancers like mantle cell lymphoma.
-
A new CAR T cell therapy targeting ovarian cancer
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
-
New CAR T-cell therapy targeting B cells for lupus treatment
This study is testing a new type of CAR T-cell therapy designed to help people with systemic lupus erythematosus (SLE) by targeting and removing the harmful B cells that contribute to the disease, with the hope of improving treatment outcomes and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.